Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like Research shows epigenetic aging in the blood as potential breast cancer marker January 21, 2025 Miniature VR headsets unlock insights into spatial memory and brain disorders December 19, 2024 Characterizing the spectrum of mitochondrial DNA deletion disease syndromes February 21, 2025